500 related articles for article (PubMed ID: 8232226)
41. Antimitotic and antitubulin activity of the tumor inhibitor steganacin.
Wang RW; Rebhum LI; Kupchan SM
Cancer Res; 1977 Sep; 37(9):3071-9. PubMed ID: 560248
[TBL] [Abstract][Full Text] [Related]
42. Interaction of marine toxin dolastatin 10 with porcine brain tubulin: competitive inhibition of rhizoxin and phomopsin A binding.
Li Y; Kobayashi H; Hashimoto Y; Shirai R; Hirata A; Hayashi K; Hamada Y; Shioiri T; Iwasaki S
Chem Biol Interact; 1994 Dec; 93(3):175-83. PubMed ID: 7923438
[TBL] [Abstract][Full Text] [Related]
43. Selective inhibition of cytokinesis in sea urchin embryos by low concentrations of stypoldione, a marine natural product that reacts with sulfhydryl groups.
O'Brien ET; Asai DJ; Jacobs RS; Wilson L
Mol Pharmacol; 1989 May; 35(5):635-42. PubMed ID: 2725473
[TBL] [Abstract][Full Text] [Related]
44. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
[TBL] [Abstract][Full Text] [Related]
45. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
Yoshimatsu K; Yamaguchi A; Yoshino H; Koyanagi N; Kitoh K
Cancer Res; 1997 Aug; 57(15):3208-13. PubMed ID: 9242451
[TBL] [Abstract][Full Text] [Related]
46. Genistein arrests cell cycle progression of A549 cells at the G(2)/M phase and depolymerizes interphase microtubules through binding to a unique site of tubulin.
Mukherjee S; Acharya BR; Bhattacharyya B; Chakrabarti G
Biochemistry; 2010 Mar; 49(8):1702-12. PubMed ID: 20085293
[TBL] [Abstract][Full Text] [Related]
47. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin.
ter Haar E; Hamel E; Balachandran R; Day BW
Anticancer Res; 1997; 17(3C):1861-9. PubMed ID: 9216636
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.
Dabydeen DA; Burnett JC; Bai R; Verdier-Pinard P; Hickford SJ; Pettit GR; Blunt JW; Munro MH; Gussio R; Hamel E
Mol Pharmacol; 2006 Dec; 70(6):1866-75. PubMed ID: 16940412
[TBL] [Abstract][Full Text] [Related]
49. Identification and characterization of A-105972, an antineoplastic agent.
Wu-Wong JR; Alder JD; Alder L; Burns DJ; Han EK; Credo B; Tahir SK; Dayton BD; Ewing PJ; Chiou WJ
Cancer Res; 2001 Feb; 61(4):1486-92. PubMed ID: 11245455
[TBL] [Abstract][Full Text] [Related]
50. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
Chang JY; Chang CY; Kuo CC; Chen LT; Wein YS; Kuo YH
Mol Pharmacol; 2004 Jan; 65(1):77-84. PubMed ID: 14722239
[TBL] [Abstract][Full Text] [Related]
51. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
Cruz-Monserrate Z; Mullaney JT; Harran PG; Pettit GR; Hamel E
Eur J Biochem; 2003 Sep; 270(18):3822-8. PubMed ID: 12950266
[TBL] [Abstract][Full Text] [Related]
52. Mechanism of action cryptophycin. Interaction with the Vinca alkaloid domain of tubulin.
Smith CD; Zhang X
J Biol Chem; 1996 Mar; 271(11):6192-8. PubMed ID: 8626409
[TBL] [Abstract][Full Text] [Related]
53. Cytotoxic activity and cytostatic mechanism of novel 2-arylbenzo[b]furans.
Yang H; Pang JY; Cai YC; Xu ZL; Xian LJ
J Pharm Pharmacol; 2006 Sep; 58(9):1281-7. PubMed ID: 16945188
[TBL] [Abstract][Full Text] [Related]
54. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
55. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro.
Jordan MA; Himes RH; Wilson L
Cancer Res; 1985 Jun; 45(6):2741-7. PubMed ID: 3986806
[TBL] [Abstract][Full Text] [Related]
56. The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog.
Mooberry SL; Leal RM; Tinley TL; Luesch H; Moore RE; Corbett TH
Int J Cancer; 2003 Apr; 104(4):512-21. PubMed ID: 12584751
[TBL] [Abstract][Full Text] [Related]
57. Interactions of antimitotic peptides and depsipeptides with tubulin.
Hamel E
Biopolymers; 2002; 66(3):142-60. PubMed ID: 12385035
[TBL] [Abstract][Full Text] [Related]
58. Microtubule-stabilizing activity of zampanolide, a potent macrolide isolated from the Tongan marine sponge Cacospongia mycofijiensis.
Field JJ; Singh AJ; Kanakkanthara A; Halafihi T; Northcote PT; Miller JH
J Med Chem; 2009 Nov; 52(22):7328-32. PubMed ID: 19877653
[TBL] [Abstract][Full Text] [Related]
59. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data.
Paull KD; Lin CM; Malspeis L; Hamel E
Cancer Res; 1992 Jul; 52(14):3892-900. PubMed ID: 1617665
[TBL] [Abstract][Full Text] [Related]
60. Rhazinilam mimics the cellular effects of taxol by different mechanisms of action.
David B; Sévenet T; Morgat M; Guénard G; Moisand A; Tollon Y; Thoison O; Wright M
Cell Motil Cytoskeleton; 1994; 28(4):317-26. PubMed ID: 7954858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
